KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short-term Investments: 2020-2024

Historic Short-term Investments for Royalty Pharma (RPRX) over the last 5 years, with Dec 2024 value amounting to $58.2 million.

  • Royalty Pharma's Short-term Investments fell 66.80% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 66.80%. This contributed to the annual value of $58.2 million for FY2024, which is 218.03% up from last year.
  • Latest data reveals that Royalty Pharma reported Short-term Investments of $58.2 million as of FY2024, which was up 218.03% from $18.3 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Short-term Investments ranged from a high of $70.0 million in FY2020 and a low of $1.3 million during FY2022.
  • Its 3-year average for Short-term Investments is $25.9 million, with a median of $18.3 million in 2023.
  • Per our database at Business Quant, Royalty Pharma's Short-term Investments tumbled by 98.03% in 2022 and then skyrocketed by 1,307.69% in 2023.
  • Over the past 5 years, Royalty Pharma's Short-term Investments (Yearly) stood at $70.0 million in 2020, then fell by 5.69% to $66.0 million in 2021, then tumbled by 98.03% to $1.3 million in 2022, then spiked by 1,307.69% to $18.3 million in 2023, then spiked by 218.03% to $58.2 million in 2024.